Premium
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C ardio‐ O ncology S tudy G roup of the H eart F ailure A ssociation of the E uropean S ociety of C ardiology in collaboration with the I nternational C ardio‐ O ncology S ociety
Author(s) -
Lyon Alexander R.,
Dent Susan,
Stanway Susannah,
Earl Helena,
BrezdenMasley Christine,
CohenSolal Alain,
Tocchetti Carlo G.,
Moslehi Javid J.,
Groarke John D.,
BerglerKlein Jutta,
Khoo Vincent,
Tan Li Ling,
Anker Markus S.,
Haehling Stephan,
Maack Christoph,
Pudil Radek,
Barac Ana,
Thavendiranathan Paaladinesh,
Ky Bonnie,
Neilan Tomas G.,
Belenkov Yury,
Rosen Stuart D.,
Iakobishvili Zaza,
Sverdlov Aaron L.,
Hajjar Ludhmila A.,
Macedo Ariane V.S.,
Manisty Charlotte,
Ciardiello Fortunato,
Farmakis Dimitrios,
Boer Rudolf A.,
Skouri Hadi,
Suter Thomas M.,
Cardinale Daniela,
Witteles Ronald M.,
Fradley Michael G.,
Herrmann Joerg,
Cornell Robert F.,
Wechelaker Ashutosh,
Mauro Michael J.,
Milojkovic Dragana,
Lavallade Hugues,
Ruschitzka Frank,
Coats Andrew J.S.,
Seferovic Petar M.,
Chioncel Ovidiu,
Thum Thomas,
Bauersachs Johann,
Andres M. Sol,
Wright David J.,
LópezFernández Teresa,
Plummer Chris,
Lenihan Daniel
Publication year - 2020
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.1920
Subject(s) - medicine , cancer , cardiotoxicity , oncology , trastuzumab , risk assessment , heart failure , intensive care medicine , breast cancer , chemotherapy , computer security , computer science
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio‐Oncology Society presents practical, easy‐to‐use and evidence‐based risk stratification tools for oncologists, haemato‐oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2‐targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi‐targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR‐ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.